Back to User profile » Dr Alexandria Lee

Papers published by Dr Alexandria Lee:


Commentary

LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

Lee ATM, Ou SI

Lung Cancer: Targets and Therapy 2024, 15:75-80

Published Date: 23 May 2024

Perspectives

Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver

Lee ATM, Ou SI

Lung Cancer: Targets and Therapy 2024, 15:19-27

Published Date: 27 February 2024

Perspectives

ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia

Lee AT, Ou SI

Lung Cancer: Targets and Therapy 2023, 14:71-78

Published Date: 7 July 2023

Commentary

From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting

Lee AT, Ou SI

Lung Cancer: Targets and Therapy 2023, 14:57-62

Published Date: 22 June 2023

Commentary

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC

Lee ATM, Nagasaka M

Lung Cancer: Targets and Therapy 2023, 14:41-46

Published Date: 25 April 2023

Commentary

CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code

Zhang SS, Lee A, Nagasaka M

Lung Cancer: Targets and Therapy 2023, 14:27-30

Published Date: 19 April 2023